Leal T, et al. Identifying resistance to immune checkpoint inhibitors by screening for PD-L1 and MHC I expression on CTCS in pts with NSCLC. IASLC 2018; abstract P3.04-08.
Brigatinib bij crizotinib-refractair ALK-positief NSCLC
jun 2017 | Longoncologie